E-MAIL UPDATES

Click here to join
our Electronic Communications.

ASX Announcements.

Date Price sens. Headline pages PDF
30/10/2020 ! Immutep enters into a Licence & Collaboration with LabCorp 2 PDF
27/10/2020   Results of Meeting 2 PDF
27/10/2020   Immutep AGM 2020 - Chairman's Address 3 PDF
27/10/2020 ! Immutep AGM 2020 - CEO Marc Voigt's Presentation 21 PDF
23/10/2020 ! COVID-19 phase 2 investigator initiated trial commences 4 PDF
22/10/2020 ! Immutep Quarterly Activities Report & Appendix 4C 9 PDF
21/10/2020 ! Immutep granted European patent for IMP761 2 PDF
19/10/2020   Immutep to present AIPAC Overall Survival data at SABCS 2020 2 PDF
06/10/2020   Change in substantial holding 6 PDF
05/10/2020   Appendix 3Y - Change of Director's Interest Notice - Mr Chamberlain 3 PDF
05/10/2020   Appendix 3Y - Change of Director's Interest Notice - Mr Meyers 3 PDF
05/10/2020   Appendix 3Y - Change of Director's Interest Notice - Mr Voigt 3 PDF
02/10/2020   Appendix 2A 17 PDF
02/10/2020   Appendix 3G 15 PDF
28/09/2020   Annual Report filed on Form 20-F with SEC 137 PDF
25/09/2020   Notice of Annual General Meeting/Proxy Form 28 PDF
25/09/2020   Appendix 4G & Corporate Governance Statement 35 PDF
25/09/2020   Annual Report to shareholders 87 PDF
18/09/2020 ! Immutep reports improving results from INSIGHT-004 trial 3 PDF
18/09/2020 ! Improving results from stage 1 of TACTI-002 Ph II  trial 4 PDF
14/09/2020   Change in substantial holding 6 PDF
11/09/2020   2020 Annual General Meeting and Key Dates 2 PDF
31/08/2020 ! IMM and Monash Uni receive funding grant for LAG-3 Research 2 PDF
26/08/2020   New data to be presented at ESMO for eftilagimod alpha 3 PDF
25/08/2020 ! Appendix 4E & 2020 Full Year Statutory Accounts 85 PDF
18/08/2020 ! Immutep Completes Recruitment for Stage 1 of Part B in TACTI-002 Study 2 PDF
17/08/2020   Immutep Investor Update 14 PDF
11/08/2020 ! Immutep Granted US Patent for Eftilagimod Alpha 2 PDF
11/08/2020   Lapse of Unlisted Options 1 PDF
27/07/2020   Change in substantial holding 6 PDF
23/07/2020 ! Immutep Quarterly Activities Report & Appendix 4C 9 PDF
21/07/2020   Change in substantial holding 6 PDF
15/07/2020 ! Immutep Announces United States Patent Grant for IMP701 Antibody 2 PDF
29/06/2020 ! Immutep Completes Recruitment for Part A of TACTI-002 trial 3 PDF
22/06/2020 ! Immutep receives A$1,437,826 R&D Tax Incentive 2 PDF
01/06/2020 ! Immutep announces improving data from TACT I - 002 ph II trial 4 PDF
01/06/2020 ! Immutep Reports First Result from INSIGHT - 004 Study 3 PDF
29/05/2020 ! Immutep Receives $3.6M R&D French Tax Incentive 2 PDF
27/05/2020   Immutep webcast to present new data from 2020 ASCO meeting 2 PDF
07/05/2020   Becoming a substantial holder from AEF 4 PDF
07/05/2020 ! Immutep Granted Japanese Patent for Eftilagimod Alpha 2 PDF
07/05/2020   Change in substantial holding 6 PDF
05/05/2020   Cleansing Notice 1 PDF
04/05/2020   Appendix 2A 16 PDF
01/05/2020   Immutep presents at NWR Virtual Small Cap Health Conference 1 PDF
30/04/2020 ! INSIGHT-004 and TACTI-002 data to be presented at ASCO 2 PDF
29/04/2020 ! Proposed issue of Securities - IMM 5 PDF
29/04/2020   Immutep Investor Presentatio 51 PDF
29/04/2020 ! Immutep completes A$12 million placement 3 PDF
28/04/2020 ! Immutep Reports Positive Phase II TACTI-002 Data 5 PDF
27/04/2020 ! Trading Halt 2 PDF
22/04/2020   Enrollment completed for the INSIGHT-004 Study 3 PDF
20/04/2020 ! Immutep March Quarterly Activities Report & Appendix 4C 10 PDF
16/04/2020 !
Immutep advances its LAG-3 agonist for autoimmune diseases
 2 PDF
14/04/2020 !
Immutep presents TACTI-002 data at AACR Virtual Meeting
 2 PDF
08/04/2020 !
EOC Pharma confirms plans to advance Efti in China for MBC
 2 PDF
26/03/2020 !
Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides
 20 PDF
25/03/2020 !
Immutep reports supportive efficacy data from AIPAC study
 4 PDF
20/03/2020  
Immutep's Partner, EOC completes recruitment of Phase 1
 3 PDF
16/03/2020  
Change of Director's Interest Notice - Mr Chamberlain
 2 PDF
09/03/2020   Immutep receives 2nd IND approval for efti from US FDA 2 PDF
02/03/2020   Change in substantial holding 6 PDF
25/02/2020   Immutep Clinical Update & Results Global Webcast Slides 23 PDF
21/02/2020   Change in substantial holding 6 PDF
21/02/2020 ! Half Yearly Report and Accounts 30 PDF
19/02/2020 ! Immutep reports positive TACTI-002 data 5 PDF
05/02/2020   Change in substantial holding 6 PDF
04/02/2020   Immutep to present TACTI-002 data at German Cancer Congress 2 PDF
29/01/2020 ! Immutep Activities Report 4 PDF
29/01/2020 ! Appendix 4C - Quarterly 5 PDF
10/01/2020   Immutep Corporate Presentation 33 PDF
09/01/2020 ! Immutep expands Part C of TACTI-002 due to positive data 2 PDF
06/01/2020   Change in substantial holding 6 PDF
02/01/2020   Change of Director's Interest Notice 3 PDF
02/01/2020   Appendix 3B 15 PDF
19/12/2019 ! INSIGHT-004 clinical trial update 3 PDF
09/12/2019   Change of Director's Interest Notice - Mr Meyers 3 PDF
09/12/2019   Change of Director's Interest Notice - Dr Howard 2 PDF
09/12/2019   Change of Director's Interest Notice - Mr Voigt 3 PDF
02/12/2019   Appendix 3B 16 PDF
22/11/2019   Immutep Investor Update 13 PDF
14/11/2019 ! Immutep announces European patent grant for LAG525 antibody 2 PDF
08/11/2019 ! IMM presents positive interim phase 2 TACTI-002 data at SITC 3 PDF
01/11/2019   Update - Consolidation Split - IMM 4 PDF
01/11/2019   2019 AGM CEO Presentation 24 PDF
01/11/2019   2019 AGM Chairman's Address 3 PDF
01/11/2019   Results of Annual General Meeting 2 PDF
31/10/2019   Consolidation/Split - IMM 4 PDF
28/10/2019 ! Operational Update 3 PDF
24/10/2019   Change in substantial holding 6 PDF
23/10/2019 ! Appendix 4C - quarterly 5 PDF
15/10/2019 ! Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial
in Melanoma		 23 PDF
10/10/2019 ! Immutep receives A$2.5M R&D French Tax Incentive 2 PDF
10/10/2019   Immutep to present data at upcoming Industry Conferences 2 PDF
04/10/2019   Change of Director's Interest Notice - Mr Chamberlain 3 PDF
04/10/2019   Change of Director's Interest Notice - Mr Meyers 3 PDF
03/10/2019   Appendix 3B 15 PDF
30/09/2019   Immutep Investor Presentation 39 PDF
30/09/2019   Notice of Annual General Meeting/Proxy Form 31 PDF
30/09/2019   Annual Report to shareholders 82 PDF
30/09/2019   Appendix 4G & Corporate Governance Statement 32 PDF
26/09/2019 ! Immutep expands Part A of TACTI-002 due to positive data 3 PDF
24/09/2019   Annual Report filed on Form 20-F with SEC 199 PDF
23/09/2019 ! Immutep to receive GBP4M Milestone Payment from GSK 2 PDF
17/09/2019 ! Japanese patent granted for LAG525 antibody 2 PDF
22/08/2019 ! Immutep granted European patent for IMP321 in cancer 2 PDF
20/08/2019 ! Appendix 4E & 2019 Full Year Statutory Accounts 83 PDF
13/08/2019   Ceasing to be a substantial holder from AEF 3 PDF
09/08/2019   Change in substantial holding 5 PDF
07/08/2019   Change of Director's Interest Notice - Mr Chamberlain 2 PDF
07/08/2019   Change of Director's Interest Notice - Mr Voigt 2 PDF
06/08/2019   Immutep completes fully underwritten A$6M Entitlement Offer 2 PDF
01/08/2019 ! Entitlement Offer Results & Shortfall Notification 2 PDF
26/07/2019 ! Operational Update 4 PDF
26/07/2019 ! Appendix 4C - quarterly 5 PDF
19/07/2019   Becoming a substantial holder from AEF 3 PDF
19/07/2019   Change in substantial holding 6 PDF
17/07/2019   Mailing of Offer Booklet for Entitlement Offer 1 PDF
17/07/2019   Cleansing Notice 1 PDF
17/07/2019  
Disclosure Under Listing Rules 3.10.5A and 7.1A.4(b)
 1 PDF
09/07/2019  
Cleansing Notice
 1 PDF
09/07/2019  
Letter to Ineligible Shareholders
 2 PDF
09/07/2019  
Letter to Eligible Shareholders
 3 PDF
09/07/2019  
Appendix 3B
 14 PDF
09/07/2019 !
Immutep Entitlement Offer Booklet
 56 PDF
09/07/2019 !
Immutep Capital Raising Presentation
 27 PDF
09/07/2019 !
Immutep raises A$10M via placement & entitlement offer
 4 PDF
05/07/2019 !
Trading Halt
 2 PDF
25/06/2019 !
Immutep completes recruitment of AIPAC trial in MBC
 3 PDF
25/06/2019  
Immutep hosts Key Opinion Leader Call
 2 PDF
21/06/2019 !
Immutep granted Australian patent for eftilagimod alpha
 2 PDF
13/06/2019 !
Immutep completes recruitment of initial NSCLC cohort
 2 PDF
06/06/2019 !
First patient dosed in INSIGHT-004
 3 PDF
03/06/2019  
Appendix 3B
 14 PDF
03/06/2019  
Immutep Poster Presentation at ASCO
 3 PDF
23/05/2019 !
Immutep granted European patent for eftilagimod alpha
 2 PDF
17/05/2019 !
More mature positive data for TACTI-mel trial presented
 2 PDF
10/05/2019  
Immutep to present at upcoming industry conferences
 2 PDF
08/05/2019  
Becoming a substantial holder
 67 PDF
30/04/2019 !
Operational Update
 4 PDF
24/04/2019 !
Appendix 4C - quarterly
 5 PDF
02/04/2019  
Webcast slides for eftilagimod alpha (IMP321)
 29 PDF
27/03/2019  
Webcast details for update on eftilagimod alpha (IMP321)
 2 PDF
26/03/2019  
Ceasing to be a substantial holder
 10 PDF
25/03/2019  
IMP761 Webcast Slides
 13 PDF
22/03/2019 !
Immutep granted US patent for IMP321
 2 PDF
19/03/2019  
Webcast to discuss IMP761 preclinical results
 2 PDF
08/03/2019 !
IMP761 results presented at ECCO conference
 2 PDF
07/03/2019 !
Immutep receives A$872,351 R&D Tax Incentive
 1 PDF
06/03/2019 !
Immutep doses First Patient in TACTI-002 Phase II Trial
 4 PDF
06/03/2019 !
TACTI-mel data presented at World Immunotherapy Congress
 3 PDF
04/03/2019  
Immutep to present at Oppenheimer Healthcare Conference
 2 PDF
27/02/2019  
Half Year Accounts
 29 PDF
26/02/2019  
Immutep to present at upcoming industry conferences
 2 PDF
25/02/2019  
Immutep Presentation to Emergence Conference
 18 PDF
31/01/2019  
Immutep Investor Update
 14 PDF
24/01/2019 !
Appendix 4C - quarterly
 5 PDF
07/01/2019 !
Immutep enters into collaboration with CYTLIMIC
 3 PDF
04/01/2019  
Change of Director's Interest Notice - Dr Howard
 3 PDF
04/01/2019  
Change of Director's Interest Notice - Mr Voigt
 4 PDF
02/01/2019  
Appendix 3B
  15 PDF
24/12/2018   Becoming a substantial holder 4 PDF
21/12/2018   Disclosure Under LR 3.10.5A and 7.1A.4(b) 2 PDF
21/12/2018   Cleansing Notice 1 PDF
21/12/2018   Appendix 3B 14 PDF
20/12/2018 ! Cleansing prospectus for issue of warrants 46 PDF
19/12/2018 ! Immutep announces US$5.2 million capital raising 3 PDF
29/11/2018 ! European patent granted for IMP321 & antibody combinations 2 PDF
28/11/2018 ! Immutep granted European patent for IMP321 2 PDF
27/11/2018 ! Immutep presents new TACTI-mel data at ICI Europe Summit 3 PDF
26/11/2018   Change of Director's Interest Notice - Dr Howard 2 PDF
21/11/2018   Appendix 3B 14 PDF
16/11/2018   Results of Meeting 3 PDF
16/11/2018   2018 AGM CEO Presentation 23 PDF
16/11/2018   2018 AGM Chairman's Address 3 PDF
12/11/2018 ! Positive interim TACTI-mel data presented at SITC 3 PDF
01/11/2018 ! Operational Update 4 PDF
30/10/2018   AusBiotech Invest presentation slides 11 PDF
25/10/2018 ! Appendix 4C - quarterly 5 PDF
22/10/2018   Annual Report filed on Form 20-F with SEC 127 PDF
11/10/2018   Notice of Annual General Meeting/Proxy Form 27 PDF
11/10/2018   Annual Report to shareholders 80 PDF
11/10/2018   Appendix 4G & Corporate Governance Statement 32 PDF
04/10/2018   Appendix 3B & cleansing notice 15 PDF
02/10/2018   Change of Director's Interest Notice - Mr Chamberlain 3 PDF
02/10/2018   Change of Director's Interest Notice - Mr Meyers 3 PDF
02/10/2018   Appendix 3B & cleansing notice 15 PDF
02/10/2018   Ceasing to be a substantial holder from AEF 3 PDF
02/10/2018   Immutep to present at SITC 2018 2 PDF
28/09/2018   Appendix 3B & cleansing notice 14 PDF
27/09/2018   Appendix 3B & cleansing notice 14 PDF
27/09/2018   Change in substantial holding from AEF 3 PDF
26/09/2018   Immutep to present at Ladenburg Thalmann conference 1 PDF
24/09/2018 ! Immutep enters into collaboration with Pfizer & Merck KGaA 4 PDF
07/09/2018   Immutep presentation for BioCentury NewsMakers conference 29 PDF
03/09/2018   Change in substantial holding from AEF 3 PDF
03/09/2018 ! Progress towards clinical development of IMP761 2 PDF
21/08/2018 ! Appendix 4E & 2018 Full Year Statutory Accounts 82 PDF
21/08/2018 ! Immutep receives A$1.9M from French R&D tax cash rebate 2 PDF
16/08/2018   Immutep to present at BioCentury NewsMakers conference 2 PDF
07/08/2018 ! Immutep secures Canadian patent grant for IMP731 antibody 2 PDF
07/08/2018 ! TACTI-mel Patient Recruitment Complete & Operational Update 3 PDF
31/07/2018 ! Immutep receives IND approval from US FDA for IMP321 2 PDF
30/07/2018 ! Appendix 4C - quarterly 5 PDF
02/07/2018 ! Immutep submits IND application with FDA 2 PDF
19/06/2018   Investor Update 13 PDF
19/06/2018 ! Mid-point of patient enrolment reached in AIPAC trial 2 PDF
04/06/2018   Immutep Poster Presentations at ASCO 2 PDF
30/05/2018 ! Webcast slides for TACTI-mel clinical trial data 25 PDF
30/05/2018 ! New Data from Ongoing TACTI-mel Study 2 PDF
25/05/2018   3rd Annual Advances in Immuno-Oncology Congress Presentation 37 PDF
17/05/2018   Webcast to discuss interim results from TACTI-mel 3 PDF
15/05/2018   Response to ASX Price Query 3 PDF
04/05/2018   Immutep to present at ASCO 2 PDF
23/04/2018   Appendix 4C 5 PDF
13/04/2018   Appendix 3B 13 PDF
13/04/2018   Completion of Share Purchase Plan 2 PDF
03/04/2018 ! Operational Update 2 PDF

 

SEC Filing.

Date Filing Description Link
2020-10-28 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-278782 (34 Act)  Size: 6 MB		 PDF-1, PDF-2, PDF-3
2020-10-26 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-276274 (34 Act)  Size: 40 KB		 PDF
2020-10-23 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-274624 (34 Act)  Size: 144 KB		 PDF
2020-10-22 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-273969 (34 Act)  Size: 30 KB		 PDF
2020-10-07 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-264945 (34 Act)  Size: 193 KB		 PDF
2020-09-25 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Acc-no: 0001193125-20-253940 (34 Act)  Size: 11 MB		 PDF
2020-09-21 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-249813 (34 Act)  Size: 83 KB		 PDF-1, PDF-2
2020-09-01 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-236488 (34 Act)  Size: 41 KB		 PDF
2020-08-27 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-231834 (34 Act)  Size: 1 MB		 PDF
2020-08-18 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-222878 (34 Act)  Size: 40 KB		 PDF
2020-08-12 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-216609 (34 Act)  Size: 44 KB		 PDF
2020-07-24 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-197957 (34 Act)  Size: 139 KB		 PDF
2020-07-16 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-193511 (34 Act)  Size: 28 KB		 PDF
2020-06-29 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-182966 (34 Act)  Size: 39 KB		 PDF
2020-06-23 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-175807 (34 Act)  Size: 23 KB		 PDF
2020-06-02 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-157640 (34 Act)  Size: 72 KB		 PDF-1, PDF-2
2020-06-01 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-155983 (34 Act)  Size: 31 KB		 PDF
2020-05-28 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-153368 (34 Act)  Size: 34 KB		 PDF
2020-05-08 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-136644 (34 Act) Size: 28 KB		 PDF
2020-05-01 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-129395 (34 Act) Size: 37 KB		 PDF
2020-04-30 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-127496 (34 Act)  Size: 22 MB		 PDF-1, PDF-2
2020-04-29 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-123665 (34 Act)  Size: 64 KB		 PDF
2020-04-23 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-115224 (34 Act)  Size: 42 KB		 PDF
2020-04-21 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-112652 (34 Act)  Size: 169 KB		 PDF
2020-04-17 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-109597 (34 Act)  Size: 35 KB		 PDF
2020-04-15 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-107327 (34 Act) Size: 34 KB		 PDF
2020-04-08 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-100811 (34 Act)  Size: 36 KB		 PDF
2020-03-30 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-089032 (34 Act)  Size: 35 KB		 PDF
2020-03-27 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-087787 (34 Act) Size: 38 KB		 PDF
2020-03-23 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-080961 (34 Act) Size: 39 KB		 PDF
2020-03-17 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-075165 (34 Act) Size: 30 KB		 PDF
2020-03-10 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-067431 (34 Act) Size: 41 KB		 PDF
2020-02-24 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-046319 (34 Act) Size: 552 KB		 PDF
2020-02-21 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-043738 (34 Act) Size: 61 KB		 PDF
2020-02-14 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001387131-20-001777 (34 Act)  Size: 94 KB		 PDF
2020-02-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-024386 (34 Act) Size: 31 KB		 PDF
2020-01-30 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-018706 (34 Act) Size: 140 KB		 PDF-1, PDF-2
2020-01-13 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-006041 (34 Act) Size: 27 KB		 PDF
2020-01-09 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]Acc-no: 0001193125-20-004200 (34 Act) Size: 36 KB PDF
2020-01-06 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-20-001860 (34 Act) Size: 191 KB		 PDF-1, PDF-2
2019-12-20 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-319328 (34 Act) Size: 32 KB		 PDF
2019-12-10 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-309656 (34 Act) Size: 77 KB		 PDF-1, PDF-2, PDF-3
2019-12-04 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-305691 (34 Act) Size: 178 KB		 PDF
2019-11-15 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-292512 (34 Act) Size: 23 KB		 PDF
2019-11-12 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-289148 (34 Act) Size: 40 KB		 PDF
2019-11-04 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-282711 (34 Act) Size: 8 MB		 PDF-1, PDF-2. PDF-3. PDF-4
2019-10-29 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-276527 (34 Act) Size: 50 KB		 PDF
2019-10-23 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-272123 (34 Act) Size: 107 KB		 PDF
2019-10-15 F-3 Registration statement by foreign private issuers
Acc-no: 0001193125-19-267683 (33 Act) Size: 359 KB		 PDF
2019-10-15 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-267232 (34 Act) Size: 38 KB		 PDF
2019-10-09 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-264613 (34 Act) Size: 52 KB		 PDF-1, PDF-2
2019-10-04 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-261937 (34 Act) Size: 171 KB		 PDF
2019-10-01 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-259428 (34 Act) Size: 13 MB		 PDF-1, PDF-2, PDF-3, PDF-4
2019-09-26 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-255307 (34 Act) Size: 35 KB		 PDF
2019-09-24 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-252416 (34 Act) Size: 23 KB		 PDF
2019-09-23 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Acc-no: 0001193125-19-252176 (34 Act) Size: 13 MB		 PDF
2019-09-18 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-247127 (34 Act) Size: 28 KB		 PDF
2019-08-22 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-226331 (34 Act) Size: 30 KB		 PDF
2019-08-21 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-225441 (34 Act) Size: 1 MB		 PDF
2019-08-14 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-220211 (34 Act) Size: 10 MB		 PDF
2019-08-14 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-220204 (34 Act) Size: 52 KB		 PDF-2
2019-08-14 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-220204 (34 Act) Size: 52 KB		 PDF-1
2019-08-07 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-214347 (34 Act) Size: 26 KB		 PDF
2019-07-30 D Notice of Exempt Offering of Securities, item 06b
Acc-no: 0001209191-19-043598 (33 Act) Size: 8 KB		 PDF
2019-07-30 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-206095 (34 Act) Size: 113 KB		 PDF
2019-07-08 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-189823 (34 Act) Size: 68 KB		 PDF
2019-06-26 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-181460 (34 Act) Size: 31 KB		 PDF
2019-06-21 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-178045 (34 Act) Size: 32 KB		 PDF
2019-06-13 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-171778 (34 Act) Size: 26 KB		 PDF
2019-06-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-165320 (34 Act) Size: 27 KB		 PDF
2019-06-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-165318 (34 Act) Size: 162 KB		 PDF
2019-05-23 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-154569 (34 Act) Size: 22 KB		 PDF
2019-05-20 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-150736 (34 Act) Size: 25 KB		 PDF
2019-05-13 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-144945 (34 Act) Size: 36 KB		 PDF
2019-05-01 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-130751 (34 Act) Size: 39 KB		 PDF
2019-04-26 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-120345 (34 Act) Size: 102 KB		 PDF
2019-04-03 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-095885 (34 Act) Size: 11 MB		 PDF
2019-03-28 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-089166 (34 Act) Size: 30 KB		 PDF
2019-03-26 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-085849 (34 Act) Size: 4 MB		 PDF
2019-03-20 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-079827 (34 Act) Size: 31 KB		 PDF
2019-03-11 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-070282 (34 Act) Size: 33 KB		 PDF
2019-03-07 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-065913 (34 Act) Size: 45 KB		 PDF
2019-03-07 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-065883 (34 Act) Size: 39 KB		 PDF
2019-03-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-062670 (34 Act) Size: 46 KB		 PDF
2019-02-28 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-055085 (34 Act) Size: 486 KB		 PDF
2019-02-27 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-052155 (34 Act) Size: 27 KB		 PDF
2019-02-27 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-050316 (34 Act) Size: 5 MB		 PDF
2019-02-14 424B3 Prospectus [Rule 424(b)(3)]
Acc-no: 0001193125-19-038345 (33 Act) Size: 337 KB		 PDF
2019-02-12 EFFECT Notice of Effectiveness
Acc-no: 9999999995-19-000221 (33 Act) Size: 1 KB		 PDF
2019-02-04 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-027147 (34 Act) Size: 2 MB		 PDF
2019-01-14 F-3 Registration statement by foreign private issuers
Acc-no: 0001193125-19-008155 (33 Act) Size: 380 KB		 PDF
2019-01-08 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-004095 (34 Act) Size: 41 KB		 PDF
2019-01-03 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-19-000902 (34 Act) Size: 146 KB		 PDF
2018-12-21 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-356488 (34 Act) Size: 305 KB		 PDF
2018-12-21 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-356410 (34 Act) Size: 168 KB		 PDF-1, PDF-2, PDF-3
2018-12-21 D Notice of Exempt Offering of Securities, item 06b
Acc-no: 0001209191-18-063797 (33 Act) Size: 10 KB		 PDF
2018-12-19 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-352838 (34 Act) Size: 27 KB		 PDF
2018-12-19 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-352630 (34 Act) Size: 490 KB		 PDF-1, PDF-2, PDF-3, PDF-4
2018-12-19 424B5 Prospectus [Rule 424(b)(5)]
Acc-no: 0001193125-18-352623 (33 Act)  Size: 488 KB		 PDF
2018-11-28 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-335585 (34 Act) Size: 32 KB		 PDF
2018-11-28 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-335435 (34 Act) Size: 36 KB		 PDF
2018-11-27 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-334115 (34 Act) Size: 27 KB		 PDF
2018-11-23 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-332532 (34 Act) Size: 193 KB PDF
2018-11-19 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-329689 (34 Act) Size: 39 KB		 PDF
2018-11-19 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-329687 (34 Act) Size: 8 MB		 PDF-2
2018-11-19 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-329687 (34 Act) Size: 8 MB		 PDF-1
2018-11-16 CT ORDER Confidential treatment order Acc-no: 9999999997-18-009006 (34 Act) Size: 105 KB PDF
2018-11-13 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-324662 (34 Act) Size: 38 KB		 PDF
2018-11-07 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-319727 (34 Act) Size: 33 KB		 PDF
2018-10-31 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-312572 (34 Act) Size: 4 MB		 PDF
2018-10-26 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-308011 (34 Act) Size: 102 KB		 PDF
2018-10-25 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-306696 (34 Act) Size: 34 KB		 PDF
2018-10-19 20-F Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-302492 (34 Act) Size: 581 KB		 PDF
2018-10-17 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-300562 (34 Act) Size: 888 KB		 PDF
2018-10-17 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-300478 (34 Act) Size: 15 MB		 PDF
2018-10-17 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-300442 (34 Act) Size: 247 KB		 PDF
2018-10-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-293981 (34 Act) Size: 127 KB		 PDF
2018-10-04 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-292668 (34 Act) Size: 184 KB		 PDF-1,  PDF-2,  PDF-3
2018-10-04 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-292527 (34 Act) Size: 119 KB		 PDF
2018-10-03 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-291188 (34 Act) Size: 23 KB		 PDF
2018-10-01 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-288121 (34 Act) Size: 118 KB		 PDF
2018-09-28 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-285992 (34 Act) Size: 114 KB		 PDF-2
2018-09-28 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-285992 (34 Act) Size: 114 KB		 PDF-1
2018-09-28 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-285955 (34 Act) Size: 28 KB		 PDF
2018-09-10 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-269333 (34 Act) Size: 2 MB		 PDF
2018-09-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-266455 (34 Act) Size: 34 KB		 PDF
2018-08-24 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-256678 (34 Act) Size: 1 MB 		 PDF-2
2018-08-24 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-256678 (34 Act) Size: 1 MB		 PDF-1
2018-08-17 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-251021 (34 Act) Size: 21 KB		 PDF
2018-08-08 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-241616 (34 Act) Size: 56 KB 		 PDF-2
2018-08-08 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-241616 (34 Act) Size: 56 KB		 PDF-1
2018-08-01 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-233634 (34 Act) Size: 24 KB		 PDF
2018-07-31 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-232248 (34 Act) Size: 108 KB		 PDF
2018-07-03 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-211709 (34 Act) Size: 35 KB		 PDF
2018-06-20 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-197123 (34 Act) Size: 3 MB		 PDF-1
PDF-2
2018-06-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-183678 (34 Act) Size: 34 KB		 PDF
2018-05-31 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-179361 (34 Act) Size: 10 MB		 PDF-1 PDF-2
2018-05-30 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-177481 (34 Act) Size: 9 MB		 PDF
2018-05-18 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-166845 (34 Act) Size: 33 KB		 PDF
2018-05-07 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-153820 (34 Act) Size: 32 KB		 PDF
2018-04-23 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-131968 (34 Act) Size: 117 KB		 PDF
2018-04-13 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-117066 (34 Act) Size: 21 KB		 PDF
2018-04-13 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-117059 (34 Act) Size: 115 KB		 PDF
2018-04-04 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Acc-no: 0001193125-18-106513 (34 Act) Size: 29 KB		 PDF

 

Financial Information.